Skip to main content
Clinical Trials/NCT05486247
NCT05486247
Completed
Not Applicable

Molecular Characterization of Gliomas Using a Broad NGS Panel

Hellenic Cooperative Oncology Group0 sites32 target enrollmentFebruary 4, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Malignant Glioma
Sponsor
Hellenic Cooperative Oncology Group
Enrollment
32
Primary Endpoint
The prevalence of genetic alterations in patients with high grade glioma using a 80 gene NGS panel
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Gliomas are the most common malignant primary brain tumors with poor prognosis. The genotyping of tumors using NGS platforms enables the identification of genetic alterations that constitute diagnostic, prognostic and predictive biomarkers.Here in, we investigated the molecular profile of 32 tumor samples from 32 patients with high grade gliomas by implementing a broad 80-gene targeted NGS panel while reporting their clinicopathological characteristics and outcomes.

Registry
clinicaltrials.gov
Start Date
February 4, 2015
End Date
May 1, 2022
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Hellenic Cooperative Oncology Group
Responsible Party
Principal Investigator
Principal Investigator

Rania Romanidou

Dr Ourania Romanidou

Hellenic Cooperative Oncology Group

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of high grade glioma based on tissue biopsy

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

The prevalence of genetic alterations in patients with high grade glioma using a 80 gene NGS panel

Time Frame: April 2019 - December 2021

The prevalence of genetic alterations in patients with high grade glioma using a 80 gene NGS panel

Similar Trials